Axogen, Inc. Common Stock (AXGN) — Analysis Summary
Axogen, Inc. Common Stock (AXGN) has a market cap of $2.18B with year-over-year revenue growth of +20.2%. Net margin stands at -7.0%. The stock trades at a P/E ratio of -64.9.
Key Takeaways
- Revenue changed +20.2% year-over-year
- Net margin of -7.0%
- P/E ratio of -64.9
Compared to other companies in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector, AXGN posted revenue growth of +20.2% and trades at a P/E of -64.9.
Axogen, Inc. Common Stock (AXGN)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -3.1x — earnings do not cover interest payments
Net income fell 113.6% vs the prior period.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Employees
622
Headquarters
ALACHUA, FL
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
N/A
Dividend Yield
N/A
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.